Literature DB >> 18751389

The Wilms' tumor suppressor WT1 inhibits malignant progression of neoplastigenic mammary epithelial cells.

Lei Wang1, Zhao-Yi Wang.   

Abstract

BACKGROUND: The Wilms' tumor suppressor gene, wt1, encodes a zinc-finger protein, WT1, that functions as a transcription regulator. Previous studies have suggested a contradictory role for WT1 in breast cancer development.
MATERIALS AND METHODS: MCF10AT3B cells, a cell line derived from a xenograft model of progressive human proliferative breast disease, were used to study WT1 function in early development of breast cancer. A stable cell line was established from MCF10AT3B cells that ectopically expressed the Wilms' tumor suppressor, WT1. Western blot analysis, in vitro and in vivo growth assays were used to study the effects of constitutive WT1 expression on malignant progression of MCF10AT3B cells.
RESULTS: WT1 expression had a profound effect on several aspects of the cell cycle machinery and inhibited estrogen-stimulated and nonstimulated cell growth in vitro. In nude mice, WT1 expression strongly suppressed estrogen-stimulated tumorigenesis of neoplastigenic MCF10AT3B cells.
CONCLUSION: WT1 plays an important role in maintaining normal growth of mammary epithelial cells and dysregulated WT1 expression may contribute to breast cancer development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18751389      PMCID: PMC2653052     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  23 in total

1.  Wilms tumor locus on 11p13 defined by multiple CpG island-associated transcripts.

Authors:  L Bonetta; S E Kuehn; A Huang; D J Law; L M Kalikin; M Koi; A E Reeve; B H Brownstein; H Yeger; B R Williams
Journal:  Science       Date:  1990-11-16       Impact factor: 47.728

2.  Atypical hyperplastic lesions of the female breast. A long-term follow-up study.

Authors:  D L Page; W D Dupont; L W Rogers; M S Rados
Journal:  Cancer       Date:  1985-06-01       Impact factor: 6.860

Review 3.  Anatomic markers of human premalignancy and risk of breast cancer.

Authors:  D L Page; W D Dupont
Journal:  Cancer       Date:  1990-09-15       Impact factor: 6.860

4.  Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus.

Authors:  K M Call; T Glaser; C Y Ito; A J Buckler; J Pelletier; D A Haber; E A Rose; A Kral; H Yeger; W H Lewis
Journal:  Cell       Date:  1990-02-09       Impact factor: 41.582

5.  Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping.

Authors:  M Gessler; A Poustka; W Cavenee; R L Neve; S H Orkin; G A Bruns
Journal:  Nature       Date:  1990-02-22       Impact factor: 49.962

6.  Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle.

Authors:  A Koff; A Giordano; D Desai; K Yamashita; J W Harper; S Elledge; T Nishimoto; D O Morgan; B R Franza; J M Roberts
Journal:  Science       Date:  1992-09-18       Impact factor: 47.728

7.  Alternative splicing and genomic structure of the Wilms tumor gene WT1.

Authors:  D A Haber; R L Sohn; A J Buckler; J Pelletier; K M Call; D E Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

8.  MCF10AT: a model for the evolution of cancer from proliferative breast disease.

Authors:  P J Dawson; S R Wolman; L Tait; G H Heppner; F R Miller
Journal:  Am J Pathol       Date:  1996-01       Impact factor: 4.307

9.  Xenograft model of progressive human proliferative breast disease.

Authors:  F R Miller; H D Soule; L Tait; R J Pauley; S R Wolman; P J Dawson; G H Heppner
Journal:  J Natl Cancer Inst       Date:  1993-11-03       Impact factor: 13.506

10.  Different roles for cyclins D1 and E in regulation of the G1-to-S transition.

Authors:  D Resnitzky; S I Reed
Journal:  Mol Cell Biol       Date:  1995-07       Impact factor: 4.272

View more
  4 in total

1.  WT1 expression in breast cancer disrupts the epithelial/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel.

Authors:  Mara Artibani; Andrew H Sims; Joan Slight; Stuart Aitken; Anna Thornburn; Morwenna Muir; Valerie G Brunton; Jorge Del-Pozo; Linda R Morrison; Elad Katz; Nicholas D Hastie; Peter Hohenstein
Journal:  Sci Rep       Date:  2017-03-27       Impact factor: 4.379

2.  WT1 Inhibits Human Renal Carcinoma Cell Proliferation and Induces G2/M Arrest by Upregulating IL-24 Expression.

Authors:  Y J Jing; L C Lin; L L Chen; Z E Huang; H C Qin; S B Li; Z H Chen
Journal:  Biomed Res Int       Date:  2022-07-23       Impact factor: 3.246

Review 3.  The role of WT1 in breast cancer: clinical implications, biological effects and molecular mechanism.

Authors:  Ye Zhang; Wen-Ting Yan; Ze-Yu Yang; Yan-Ling Li; Xuan-Ni Tan; Jun Jiang; Yi Zhang; Xiao-Wei Qi
Journal:  Int J Biol Sci       Date:  2020-02-24       Impact factor: 6.580

4.  WT1 expression in vessels varies with histopathological grade in tumour-bearing and control tissue from patients with breast cancer.

Authors:  Richard J McGregor; You-Ying Chau; Timothy J Kendall; Mara Artibani; Nicholas Hastie; Patrick W F Hadoke
Journal:  Br J Cancer       Date:  2018-10-30       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.